• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Stroke prevention in women: synopsis of the 2014 american heart association/american stroke association guideline.
Abstract DESCRIPTION: In February 2014, the American Heart Association/American Stroke Association released their first guideline focused on stroke prevention in women. This new guideline highlights unique risk factors for stroke in women, including oral contraception and hormone therapy, and pregnancy-associated disorders, such as preeclampsia, that may have long-lasting consequences on a woman's health. It also addresses hypertension; atrial fibrillation; migraine headache with aura; and the epidemiology of types of stroke, such as aneurysmal subarachnoid hemorrhage and cerebral vein thrombosis, that are predomi...
Source: Annals of Internal Medicine - June 17, 2014 Category: Internal Medicine Authors: Bushnell C, McCullough L Tags: Ann Intern Med Source Type: research

The risk of fatal stroke in Finnish postmenopausal hormone therapy users before and after the Women's Health Initiative: A cohort study
Stroke is the third most common cause of death and the most common cause of prolonged disability in women worldwide[1]. Therefore, the American Heart and Stroke Association recently published strict new guidelines for the prevention of stroke in women [2]. These guidelines acknowledge a number of female gender-related risk factors for stroke, such as migraine, pregnancy, pre-eclampsia, atrial fibrillation, obesity, metabolic syndrome, living alone -status and consequent delay in thrombolysis, and longevity.
Source: Maturitas - April 13, 2015 Category: Primary Care Authors: Pauliina Tuomikoski, Heli Lyytinen, Pasi Korhonen, Fabian Hoti, Pia Vattulainen, Mika Gissler, Olavi Ylikorkala, Tomi S. Mikkola Source Type: research

Many Women Unaware of Female-Specific Stroke Symptoms
Pregnancy, migraines and hormone therapy put women at increased risk, researchers say Source: HealthDay Related MedlinePlus Pages: Stroke, Women's Health
Source: MedlinePlus Health News - May 7, 2015 Category: Consumer Health News Source Type: news

Migraine and menopause - a narrative review
Discussion and conclusion: Many women are informed that their migraines will disappear postmenopause; there are some data to support this, but a specific time frame has not been evidenced. Stroke risk in women with migraine with aura is small in absolute terms, but important at the population level, because migraine is so prevalent. The risk becomes clinically important in the context of additional stroke risk factors, which increase with aging such as hypertension. Estrogen in combined hormonal contraception increases the risk of an ischemic stroke, however, the lower amount of estrogen in HT may not contribute to a m...
Source: Menopause - January 1, 2021 Category: OBGYN Tags: Review Articles Source Type: research

Sex and Gender Considerations in Episodic Migraine
AbstractPurpose of ReviewWe seek to update readers on recent advances in our understanding of sex and gender in episodic migraine with a two part series. In part 1, we examine migraine epidemiology in the context of sex and gender, differences in symptomatology, and the influence of sex hormones on migraine pathophysiology (including CGRP). In part 2, we focus on practical clinical considerations for sex and gender in episodic migraine by addressing menstrual migraine and the controversial topic of hormone-containing therapies. We make note of data applicable to gender minority populations, when available, and summarize kn...
Source: Current Pain and Headache Reports - June 9, 2022 Category: Neurology Source Type: research

FDA Approval of Paroxetine for Menopausal Hot Flushes
ABSTRACT: In June 2013, the Food and Drug Administration (FDA) approved paroxetine (Brisdelle, Noven) for the treatment of moderate to severe hot flushes (vasomotor symptoms) associated with menopause. Brisdelle is the only nonhormonal treatment approved by the FDA for this indication. Prior to approval of Brisdelle, FDA-approved treatments for hot flashes were hormones containing either estrogen alone or estrogen plus a progestin. Hormonal therapy is highly effective for treating vasomotor symptoms. However, the use of hormonal therapy dropped substantially after initial findings of the Women’s Health Initiative randomi...
Source: Obstetrical and Gynecological Survey - October 1, 2014 Category: OBGYN Tags: Gynecology: Office Gynecology Source Type: research

Menopausal hormone therapy, depression, headache, vasomotor symptoms and absence from work: results from 3 years follow up in a Dutch gynecology clinic
Introduction: Use of menopausal hormone therapy (MHT) has dropped worldwide during the last decade after the ‘Women's Health Initiative’ (WHI) trial reported increased breast cancer, stroke and embolism risk. Women with bothersome menopausal complaints resorted to complementary and alternative medications with less or unproven efficacy. Even when indicated use of MHT is low and of short duration, possibly affecting individual wellbeing and ability to work.
Source: Maturitas - April 21, 2015 Category: Primary Care Authors: Mojdeh Shayesteh, Ingrid Pinas Tags: O5 Source Type: research

Many Women Unaware of Female-Specific Stroke Symptoms
Pregnancy, migraines and hormone therapy put women at increased risk, researchers say
Source: WebMD Health - May 7, 2015 Category: Consumer Health News Source Type: news

Bioidentical hormones for women with vasomotor symptoms.
CONCLUSIONS: There was low to moderate quality evidence that BHT in various forms and doses is more effective than placebo for treating moderate to severe menopausal hot flushes. There was low to moderate quality evidence of higher rates of adverse effects such as headache, vaginal bleeding, breast tenderness and skin reactions in the BHT group. There was some evidence to suggest that higher doses of BHT are associated with greater effectiveness but also with higher risk of adverse effects. Although all the included studies used unopposed estrogen, it is recommended best practice to use progestogen therapy in women with a ...
Source: Cochrane Database of Systematic Reviews - July 31, 2016 Category: Journals (General) Authors: Gaudard AM, Silva de Souza S, Puga ME, Marjoribanks J, da Silva EM, Torloni MR Tags: Cochrane Database Syst Rev Source Type: research

Hormone Therapy May Be OK for Women With Migraines
Heightened risk of stroke not borne out in preliminary study
Source: WebMD Health - October 11, 2017 Category: Consumer Health News Source Type: news

Endocrine disorders in a patient with a suspicion of a mitochondrial disease, MELAS syndrome - a case report and literature review
We present a girl who was suspected of MELAS syndrome during the diagnostic evaluation of short stature. The patient suffered from symptoms potentially indicating mitochondrial disease, such as muscular weakness, cranial nerve VI palsy, headaches, retinitis pigmentosa, sensory-neural hearing loss, and elevated lactic acid. T2-weighted brain MRI showed hyperintense lesions in the white matter. Muscular biopsy revealed ragged red fibres. Genetic evaluation did not detect the most common mutations in the MT-TL1 gene and MT-ND5 gene. Endocrine tests led to the confirmation of growth hormone deficiency, and so replacement treat...
Source: Pediatric Endocrinology, Diabetes, and Metabolism - October 1, 2021 Category: Endocrinology Authors: Marta Baszy ńska-Wilk El żbieta Moszczyńska Maria Szarras-Czapnik Marta Wysocka-Mincewicz Urszula W ątrobińska Agata Koz łowska Mieczys ław Szalecki Source Type: research

Pages: 1  2  3